Clinical Trials

100 enrolled

Carcinoma, Renal Cell

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

60 enrolled

Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05987241 2026-04-15

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

992 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

31 enrolled

Carcinoma, Renal Cell

NCT06638931 2026-04-15

ANTARES

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

28 enrolled

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Phase 1 Not yet recruiting

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT06053658 2026-04-14

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

48 enrolled

Carcinoma, Renal Cell

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02496208 2026-04-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03793166 2026-04-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

1,175 enrolled

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT05048212 2026-04-09

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

20 enrolled

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

15 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04709276 2026-04-06

CHAMP

41 enrolled

Prostatic Neoplasms

NCT06863311 2026-04-03

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT07188896 2026-04-03

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07401875 2026-04-02

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Phase 1/2 Active not recruiting

Kidney Neoplasms

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT05267626 2026-03-31

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

159 enrolled

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT07293351 2026-03-31

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

234 enrolled

Carcinoma, Renal Cell

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

450 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07494435 2026-03-27

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

230 enrolled

Carcinoma, Renal Cell

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

8 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2 Terminated

15 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05176483 2026-03-12

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

14 enrolled

Prostatic Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

1,116 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

31 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06284564 2026-03-04

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

10 enrolled

Carcinoma, Renal Cell

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04610671 2026-02-27

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase 1 Completed

21 enrolled

Urinary Bladder Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

52 enrolled